• Je něco špatně v tomto záznamu ?

Antitubercular nanocarrier monotherapy: Study of In Vivo efficacy and pharmacokinetics for rifampicin

J. Trousil, O. Pavliš, P. Kubíčková, M. Škorič, V. Marešová, E. Pavlova, KD. Knudsen, YS. Dai, M. Zimmerman, V. Dartois, JY. Fang, M. Hrubý

. 2020 ; 321 (-) : 312-323. [pub] 20200214

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020558

Grantová podpora
S10 OD023524 NIH HHS - United States

Tuberculosis represents a major global health problem for which improved approaches are needed to shorten the course of treatment and to combat the emergence of resistant strains. The development of effective and safe nanobead-based interventions can be particularly relevant for increasing the concentrations of antitubercular agents within the infected site and reducing the concentrations in the general circulation, thereby avoiding off-target toxic effects. In this work, rifampicin, a first-line antitubercular agent, was encapsulated into biocompatible and biodegradable polyester-based nanoparticles. In a well-established BALB/c mouse model of pulmonary tuberculosis, the nanoparticles provided improved pharmacokinetics and pharmacodynamics. The nanoparticles were well tolerated and much more efficient than an equivalent amount of free rifampicin.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020558
003      
CZ-PrNML
005      
20210830102215.0
007      
ta
008      
210728s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jconrel.2020.02.026 $2 doi
035    __
$a (PubMed)32067995
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Trousil, Jiří $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského náměstí 2, 162 00 Prague 6, Czechia; Department of Analytical Chemistry, Faculty of Science, Charles University, Hlavova 8, 128 43 Prague 2, Czechia. Electronic address: trousil@imc.cas.cz
245    10
$a Antitubercular nanocarrier monotherapy: Study of In Vivo efficacy and pharmacokinetics for rifampicin / $c J. Trousil, O. Pavliš, P. Kubíčková, M. Škorič, V. Marešová, E. Pavlova, KD. Knudsen, YS. Dai, M. Zimmerman, V. Dartois, JY. Fang, M. Hrubý
520    9_
$a Tuberculosis represents a major global health problem for which improved approaches are needed to shorten the course of treatment and to combat the emergence of resistant strains. The development of effective and safe nanobead-based interventions can be particularly relevant for increasing the concentrations of antitubercular agents within the infected site and reducing the concentrations in the general circulation, thereby avoiding off-target toxic effects. In this work, rifampicin, a first-line antitubercular agent, was encapsulated into biocompatible and biodegradable polyester-based nanoparticles. In a well-established BALB/c mouse model of pulmonary tuberculosis, the nanoparticles provided improved pharmacokinetics and pharmacodynamics. The nanoparticles were well tolerated and much more efficient than an equivalent amount of free rifampicin.
650    _2
$a zvířata $7 D000818
650    12
$a antituberkulózní antibiotika $x farmakokinetika $7 D000904
650    _2
$a antituberkulotika $7 D000995
650    _2
$a nosiče léků $7 D004337
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední BALB C $7 D008807
650    12
$a Mycobacterium tuberculosis $7 D009169
650    _2
$a nanostruktury $7 D049329
650    12
$a rifampin $x farmakokinetika $7 D012293
650    12
$a tuberkulóza $x farmakoterapie $7 D014376
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pavliš, Oto $u Center of Biological Defense, Military Health Institute, Military Medical Agency, 561 66 Těchonín, Czechia
700    1_
$a Kubíčková, Pavla $u Center of Biological Defense, Military Health Institute, Military Medical Agency, 561 66 Těchonín, Czechia
700    1_
$a Škorič, Miša $u Department of Pathology and Parasitology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czechia
700    1_
$a Marešová, Věra $u Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Ke Karlovu 2, 121 08 Prague 2, Czechia
700    1_
$a Pavlova, Ewa $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského náměstí 2, 162 00 Prague 6, Czechia
700    1_
$a Knudsen, Kenneth D $u Department of Physics, Institute for Energy Technology, P. O. Box 40, N-2027 Kjeller, Norway
700    1_
$a Dai, You-Shan $u Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan
700    1_
$a Zimmerman, Matthew $u Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103, USA
700    1_
$a Dartois, Véronique $u Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103, USA
700    1_
$a Fang, Jia-You $u Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan
700    1_
$a Hrubý, Martin $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského náměstí 2, 162 00 Prague 6, Czechia. Electronic address: hruby@imc.cas.cz
773    0_
$w MED00002621 $t Journal of controlled release : official journal of the Controlled Release Society $x 1873-4995 $g Roč. 321, č. - (2020), s. 312-323
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32067995 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102215 $b ABA008
999    __
$a ok $b bmc $g 1691182 $s 1141004
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 321 $c - $d 312-323 $e 20200214 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
GRA    __
$a S10 OD023524 $p NIH HHS $2 United States
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace